Literature DB >> 15797756

Novel use of sildenafil in the treatment of portopulmonary hypertension.

Roderick Chua1, Anne Keogh, Masami Miyashita.   

Abstract

Portopulmonary hypertension is a poorly understood and uncommon complication of advanced chronic liver disease. Current therapy is based largely on treatment options proven in idiopathic pulmonary hypertension. The severity of the portopulmonary hypertension should best be attenuated medically before attempting combined liver and lung transplantation to avoid increased peri-operative mortality. This case report describes the successful use of sildenafil to decrease the pulmonary vascular resistance in a patient with hepatitis-C cirrhosis who was preparing for liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797756     DOI: 10.1016/j.healun.2004.01.017

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

Review 1.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

Review 2.  Treatment Barriers in Portopulmonary Hypertension.

Authors:  Batool AbuHalimeh; Michael J Krowka; Adriano R Tonelli
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

Review 3.  Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations.

Authors:  Mortada H F El-Shabrawi; Naglaa M Kamal
Journal:  Paediatr Drugs       Date:  2011-12-01       Impact factor: 3.022

Review 4.  Hepatopulmonary syndrome: update on pathogenesis and clinical features.

Authors:  Junlan Zhang; Michael B Fallon
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-07-03       Impact factor: 46.802

5.  Portopulmonary hypertension.

Authors:  Sarfraz Saleemi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

Review 6.  Management of portopulmonary hypertension: new perspectives.

Authors:  Luigi Mancuso; Francesca Scordato; Michela Pieri; Eliana Valerio; Andrea Mancuso
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

7.  Management of cardiopulmonary complications of cirrhosis.

Authors:  Prabha Sawant; C Vashishtha; M Nasa
Journal:  Int J Hepatol       Date:  2011-07-19

Review 8.  Sildenafil in the treatment of pulmonary hypertension.

Authors:  Christopher F Barnett; Roberto F Machado
Journal:  Vasc Health Risk Manag       Date:  2006

9.  Hepatopulmonary syndrome and portopulmonary hypertension.

Authors:  Adrian Hendrickse; Fareed Azam; M Susan Mandell
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-04

10.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Portopulmonary hypertension.

Authors:  Sarfraz Saleemi; Majdy M Idrees
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.